Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
Methotrexate treatment is associated with good long-term neurocognitive outcomes
October 25th, 2006
Treatment strategies for young children with acute lymphoblastic leukemia (ALL) that avoid cranial radiation therapy (CRT) are associated with good long-term neurocognitive outcomes. "CRT is associated with neurocognitive morbidity in survivors of childhood ALL. For most patients, CRT has been replaced with intensified systemic and intrathecal chemotherapy, often including methotrexate (MTX). The impact of chemotherapy-only protocols on neurocognitive outcomes is unclear, and the importance of systemic MTX dose has not been established," investigators in Canada report. "Seventy nine of 120 eligible children diagnosed with high-risk ALL between the...
Source: Biotech Week (2006-10-25)
|
